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Cost-Effectiveness of Cycloplegic Agents: Results of a
Randomized Controlled Trial in Nigerian Children
Anne Ebri,1 Hannah Kuper,2 and Susanne Wedner2
PURPOSE. To compare the cost and effectiveness of three cyclo-
plegic agents among Nigerian children.
METHODS. Two hundred thirty-three children aged 4 to 15 years
attending outpatient eye clinics in Nigeria were randomized to
(1) 1% cyclopentolate, (2) 1% cyclopentolate and 0.5% tropic-
amide, or (3) 1% atropine drops in each eye (instilled at home
over 3 days). Ten children were lost to follow-up, nine from
the atropine group. An optometrist measured the residual
accommodation (primary outcome), dilated pupil size, pupil
response to light, and self-reported side effects (secondary
outcomes). Caregivers were interviewed about costs incurred
due to cycloplegia (primary outcome). The incremental cost
effectiveness ratios (ICERs) were calculated as the difference in
cost divided by the difference in effectiveness comparing two
agents. The 95% confidence intervals (CI) for ICERs were
estimated through bootstrapping.
RESULTS. The atropine group had significantly lower mean re-
sidual accommodation (0.04  0.01 D [SE]), than the com-
bined regimen (0.36  0.05 D) and cyclopentolate (0.63 
0.06 D) groups (P  0.001). Atropine and the combined
regimen produced better results for negative response to light
and dilated pupil size than cyclopentolate. Atropine was more
expensive, but also more effective, than the other agents. The
ICER comparing atropine to the combined regimen was 1.81
(95% CI  6.31–15.35) and compared to cyclopentolate was
0.59 (95% CI3.47–5.47). The combined regimen was both
more effective and less expensive than cyclopentolate alone.
CONCLUSIONS. A combination of cyclopentolate and tropicamide
should become the recommended agent for routine cyclople-
gic refraction in African children. The combined regimen was
more effective than cyclopentolate, but not more expensive,
and was preferable to atropine, since it incurred fewer losses
to follow-up. (Invest Ophthalmol Vis Sci. 2007;48:1025–1031)
DOI:10.1167/iovs.06-0604
In the Refractive Error Study in Children (RESC), standardizedmethods were used to measure the prevalence and causes of
visual impairment in children in different international set-
tings.1 Estimates of visual impairment (presenting visual acuity
[VA] 6/12 in the better eye) ranged from 1.2% in South
African children aged 5 to 15 years,2 up to 10.1% in Malaysian
children aged 7 to 15 years.3 Uncorrected significant refractive
error was the main cause of visual impairment in all RESC
settings, and provision of correct spectacles would have re-
duced considerably the prevalence of visual impairment, for
instance, to only 0.3% in South African and 1.4% in Malaysian
children.2,3 These data show that uncorrected significant re-
fractive error in children is a substantial, yet avoidable, prob-
lem that could have adverse effects on academic performance
and professional development in later life. The provision of
spectacles to children with uncorrected refractive error has
therefore been made a priority of VISION 2020: The Right to
Sight, the global initiative of the World Health Organization
(WHO) and the International Agency for Prevention of Blind-
ness, for the elimination of avoidable blindness by the year
2020.4
Cycloplegic refraction is needed to measure refractive error
accurately in children, as it inhibits accommodation during
refraction and thereby prevents the overestimation of myopia
and the underestimation of hyperopia.5 Atropine, cyclopento-
late, and tropicamide are the most commonly used cycloplegic
agents.6,7 Atropine produces the greatest amount of cyclople-
gia, making it the gold standard, but it has logistic drawbacks,
as it can produce severe side effects, requires prolonged re-
covery, and necessitates the examination of the child a few
days after administration.6,7 In contrast, cyclopentolate and
tropicamide have a relatively short duration of action and so
are used widely in clinical practice, and cycloplegic refraction
with cyclopentolate eye drops was used in all RESC studies.1,6
There is concern, however, that cyclopentolate and tropicam-
ide on their own are less effective cycloplegic agents in chil-
dren with dark irides than in those with light irides8,9 and
could lead to underestimation of the prevalence and severity of
hyperopia in African and Asian populations.10 As an example,
the RESC in South African children reported that approxi-
mately half of the children whose eyes were dilated with
cyclopentolate had inadequate cycloplegia,2 and inadequate
cycloplegia was also reported in the RESC in Malaysia and in
India.3,11 Tropicamide 1% on its own is not a suitable alterna-
tive cycloplegic agent in an African setting as it is less effective
than cyclopentolate in inhibiting accommodation,12 and its
effectiveness seems to vary with ethnicity.13 Another draw-
back of tropicamide is that its maximum cycloplegic effect lasts
less than 1 hour, making it impractical for use in a busy African
outpatient clinic.6 Tropicamide in combination with cyclopen-
tolate may increase cycloplegia in children with dark irides,
while remaining fast acting, and this may provide the best
alternative to atropine.14,15
The purpose of this study was to compare the cost and
effectiveness of three cycloplegic drug regimens (atropine,
cyclopentolate, and a combination of cyclopentolate and tropi-
camide) in a randomized controlled trial in Nigerian children
aged 4 to 15 years.
METHODS
Participants
The trial was conducted in Akwa Ibom and Cross River States in South
Eastern Nigeria. Children aged 4 to 15 years who presented with an eye
complaint at the Abak eye center or the Ministry of Health eye center
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between May 5 and July 5 2005 were eligible for participation. Chil-
dren were excluded if they had anterior segment disorders severe
enough to interfere with retinoscopy (e.g., corneal scar or lens opac-
ity), a history of corneal or cataract surgery, glaucoma, or known
allergies to any of the cycloplegic drops used. Children with irides that
were not brown (i.e., green or albino) were also excluded, as the
purpose of the study was to compare the cost-effectiveness of cyclo-
plegic agents for dark irides.
Ethical Considerations
Ethics approval was granted by the ethics committees of the University
of Calabar Teaching Hospital, Nigeria, and of the London School of
Hygiene and Tropical Medicine. The study was explained to the chil-
dren and their parents. Written consent was obtained from all parents
and verbal assent from all children who agreed to participate. All data
were kept confidential throughout the study. The research adhered to
the tenets of the Declaration of Helsinki.
Interventions
There were three treatment arms in the trial:
1. Atropine 1% eye drops: 1 drop instilled three times daily for 3
days, administered by the child’s parents after verbal and writ-
ten instructions had been provided.
2. Cyclopentolate 1% eye drops: 2 single drops administered by a
nurse 5 minutes apart.
3. Cyclopentolate 1% and tropicamide 0.5% eye drops: 1 drop of
each followed by a second drop of each after 5 minutes, admin-
istered by a nurse.
Objectives
The objectives of this study were:
1. To compare the cycloplegic effect of the three regimens in
Nigerian children with dark irides.
2. To compare the effect on pupillary dilation and response to
light and self-reported side effects of agent.
3. To compare the costs of the three regimens.
Outcomes
Costs. The parents or guardians of eligible children who had
agreed to participate were interviewed by trained hospital personnel.
They were asked about their out-of-pocket expenses, both direct and
productivity costs, incurred as a result of the cycloplegic refraction.
Direct costs are those that arose directly from delivering the interven-
tion, including travel costs and any other costs such as accommodation
and food directly attributable to the cycloplegic refraction. Productiv-
ity costs, refer to changes in productivity on account of the interven-
tion, including (as applicable) the carer’s wages lost because the carer
had to accompany the child to the clinic, the children’s wages lost, or
the children’s school fees lost because the child was at the clinic for
the cycloplegic refraction. The parents/guardians were also questioned
about their sociodemographic status and their child’s ocular and gen-
eral medical history.
Ophthalmic Examination before Cycloplegia. VA of the
children was tested by an ophthalmic assistant using a logMAR E-chart
at 4 m illuminated with two fluorescent strip bulbs. VA results were
converted and reported in 6-m equivalents. The anterior segment was
examined by an optometrist and an ophthalmologist using a pen torch
and a slit lamp (Haag Streit, Wedel, Germany), and ocular motility was
measured by assessing the corneal reflex and neutralization with prisms.
The children were refracted in a dark room by an optometrist (AE)
using a streak retinoscope (Keeler, Windsor, UK) at a measuring
distance of 66 cm, equivalent to 1.5 D fixating an object at 6 m. This
was followed by subjective refraction and direct ophthalmoscopy of
the posterior pole (Keeler). Refractive errors were described by using
spherical equivalents for the right eye, since there was a high correla-
tion between VA for the right and left eyes. A child was classified as
myopic if the spherical equivalent was 0.5 D or worse and as
hyperopic if the spherical equivalent was 1.0 D or worse. Children
with a spherical equivalent between 0.5 D and 1.0 D were classi-
fied as emmetropic.
Ophthalmic Examination with Cycloplegia. After cyclo-
plegia, children had their pupil dilatation and response to light mea-
sured by two independent optometrists who were not aware of their
colleague’s measurement. Pupil dilation was assessed by measuring the
pupillary diameter with a ruler to the nearest millimeter and pupillary
reaction to light was graded as “response to light” or “no response to
light.” For five children there was a 1-mm difference in pupillary
diameter between the optometrists and/or disagreement on pupillary
reaction to light, and so an ophthalmologist repeated the examination.
In all five cases, the ophthalmologist agreed with one of the optome-
trists’ assessments, and so the consensus measurement was recorded.
Cycloplegic objective refraction was performed by distance retinos-
copy by the same technique as was used for noncycloplegic refraction.
Dynamic near retinoscopy was performed while children moved fixa-
tion from a distance object at 6 m to a near object at 40 cm. All
retinoscopies were performed by the same optometrist (AE). The study
ophthalmologist examined the anterior and posterior segment with a
slit lamp and by direct ophthalmoscopy. After the examination, the
children (or parents of young children) were asked by a trained
optometrist or auxiliary nurse whether they had experienced any side
effects from the agent. The children were classified as having side
effects if they complained about pain, stinging, profuse tearing, or
discomfort or if tearing was observed.
Primary and Secondary Outcomes. The primary outcome
measures were the mean residual accommodation and the mean total
cost for each regimen. Residual accommodation was determined by
subtracting the cycloplegic near retinoscopy results from the cyclople-
gic distance retinoscopy results.
Secondary outcome measures were (1) the proportion of children
whose pupils were dilated to 6 mm (2) the proportion of children
whose pupils did not contract when exposed to the light of a pen
torch, and (3) the proportion of children who reported side effects
from the agent.
Sample Size
A sample size of 78 children in each of the three intervention arms was
necessary, to detect a difference of at least 0.25 D in residual accom-
modation between the interventions, with 80% power and a 5% con-
fidence level and allowing for 10% loss to follow-up.
Randomization and Masking
Children were randomly assigned to one of the three intervention
arms. The intervention group was concealed in numbered, opaque
envelopes which were contained in a box. Each child selected one
envelope and gave it to the nurse, who opened the envelope. If the
child was assigned to the cyclopentolate or combined-regimen group,
then the nurse administered the appropriate cycloplegic agent at that
time. If the child was assigned to the atropine group, then the nurse
gave verbal instructions in the native dialect to the parents on how to
administer the atropine drops at home and gave the parents an instruc-
tion leaflet and application chart. The parents of the children in the
atropine group were instructed to bring the child back to the dilation
room on the third day with the used bottle of atropine. The nurse
recorded the child’s name, identification number and type of drug on
a form that was not available to the study optometrist. Children who
had been given short-acting cycloplegic drugs were examined after 30
minutes and children given atropine were examined after 3 days. The
masking of the optometrist was incomplete, because children in dif-
ferent treatment groups were examined at different time intervals.
Statistical Methods
All data were checked for consistency and completeness at the end of
each day. Data were entered onto computers (EpiData; EpiData Asso-
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ciation, Odense, Denmark) and verified against the paper copy. Range
and consistency tests were performed before the data were analyzed
(SPSS ver. 11.6; SPSS, Chicago, IL).
Statistical analysis was performed in only the right eye, because the
results in the left and right eyes were similar. Continuous data were
described using means and standard errors for normally distributed
data, whereas medians, quartiles, and ranges were used for data that
were not normally distributed. Categorical data were described using
frequencies and percentages. Normally distributed continuous data
were tested for significance using the Student’s t-test or the analysis of
variance (ANOVA). The Wilcoxon rank sum test was used for contin-
uous data that did not follow a normal distribution, and the Pearson’s
2 test was used for categorical data.
Mean and median costs incurred as a result of the intervention were
calculated for the three regimens. For children who had extremely
high costs (i.e., in the 99th percentile), the costs of children’s school
fees lost were truncated at £1 per day (three children) and transport
costs were truncated at £4 (two children). The incremental costs and
effectiveness of the three treatments were compared in a cost-effec-
tiveness analysis.16 The mean difference in effectiveness (i.e., residual
accommodation) and costs were calculated comparing two cyclople-
gic agents in turn. The incremental cost-effectiveness ratio (ICER) was
calculated as the difference in cost between the two agents divided by
the difference in effectiveness. This gives the additional cost per 1-D
decrease in residual accommodation for one agent compared to an-
other. It is assumed that the mean additional cost for a 1-D reduction
in residual accommodation is twice the mean additional cost of a 0.5-D
reduction. A sampling distribution of the incremental costs and effec-
tiveness was estimated through nonparametric bootstrapping with
1000 replications, a simulation method for statistical inference.17 Each
bootstrap sample was obtained by repeated random sampling with
replacement from the original data points. A bootstrap ICER was
calculated for each of the 1000 bootstrap replicates. The 95% CIs for
the ICERs comparing two cycloplegic agents were calculated from the
2.5 and 97.5 percentile of the ICERs. The bootstrapped ICERs were
graphically represented on a cost-effectiveness plane, which shows the
relative costs and effectiveness of the two agents.18 All costs and
benefits were measured at the present time and were not discounted
(i.e., when we reduce the value given to future costs and future
benefits in relation to how far in the future they are measured).
RESULTS
Participant Flow
Two hundred forty-seven children aged 4 to 15 years were
assessed for eligibility, 183 identified from the Abak eye center
and 64 from the Ministry of Health eye center in Calabar (Fig.
1). Of these, 14 children were excluded because of pupil
anomalies (n  4), uniocular lens opacity (n  2), ocular
albinism (n  2), suspected glaucoma (n  2), pseudophakia
(n  2), uniocular aphakia (n  1), or green iris (n  1). The
remaining 233 children were randomly allocated to the cyclo-
pentolate (n 76), combined regimen (n 78) or atropine (n
 79) groups. Ten children were lost to follow-up: nine from
the atropine group who did not return after 3 days and one
child from the combined-regimen group who refused to con-
tinue after the first drops. All 10 were boys. Those lost to
follow-up were younger (mean, 9.3  0.6 years [SE]) than
those included (mean, 10.4  0.2 years) and had a slightly
higher refractive error (mean,0.5 0.1 D vs.0.4 0.1 D).
The results were analyzed for the remaining 223 children.
Baseline Data
Sociodemographic and ophthalmic characteristics were similar
in the three groups (Table 1). The mean age was 10.1  0.23
years in the cyclopentolate group, 10.6  0.32 years in the
combined-regimen group, and 10.4  0.29 years in the atro-
pine group. There were slightly more girls in the combined-
FIGURE 1. Flow diagram of the
progress through the phases of the
randomized trial.
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regimen group (67%) than in the others (55% in cyclopentolate
and 47% in atropine), though the difference did not reach
statistical significance. The educational status of the three
groups was similar. In each of the three groups, most of the
children were emmetropic or hyperopic, and few were myo-
pic.
Effectiveness of Cycloplegic Agents
The primary outcome for effectiveness in this study was mean
residual accommodation. Significantly lower mean residual ac-
commodation was achieved in the atropine group (mean,
0.04  0.01 D [SE]), than in the combined-regimen (0.36 
0.05 D) or cyclopentolate (0.63D 0.06 D; P 0.0001) group.
None of the children in the atropine group had a residual
accommodation 0.5 D, compared with 22 in the combined-
regimen group (29%), and 35 children in the cyclopentolate
group (46%; Table 2). All the children in the atropine group
had a dilated pupil size of at least 6 mm, which was achieved
by all except five (94%) children in the combined-regimen
group, but only 40 (53%) of the 76 children in the cyclopen-
tolate group. Response to light was negative in 97% of the
children in the atropine group (68/70), 66% of the combined-
regimen group (51/77), and only 25% of the cyclopentolate-
treated children (19/76). Self-reported (or, for younger chil-
dren, parent reported) side effects were mild and associated
with instillation of drops (stinging sensation, 52% of side ef-
fects; peppery sensation, 30%; discomfort, 15%; haloes around
colors, 2%). Only 5 (7%) of 70 subjects in the atropine group
had side effects from the agent, compared with 22 (29%) of 76
subjects in the cyclopentolate group and 22 (29%) of 77 sub-
jects in the combined-regimen group. However, all the chil-
dren in the atropine group reported prolonged blurry near
vision when they were refracted 3 days after the initial exam-
ination. No systemic side effects were reported.
TABLE 1. Baseline Characteristics of Participants in the Three Intervention Arms
Cyclopentolate
(n  76)
Combined Regimen
(n  77)
Atropine
(n  70)
P
Pearson 2
Age (y)
4–6 6 (8) 9 (12) 6 (9) 0.43
7–9 26 (34) 16 (21) 18 (26)
10–12 30 (39) 28 (36) 28 (40)
13–15 14 (18) 24 (31) 18 (26)
Sex
Male 34 (45) 28 (36) 37 (53) 0.13
Female 42 (55) 49 (67) 33 (47)
Education*
Preschool 3 (4) 4 (5) 1 (1) 0.79
Primary 47 (62) 44 (59) 43 (61)
Secondary 26 (34) 27 (36) 26 (37)
Glasses
Yes 13 (17) 16 (21) 13 (19) 0.84
No 63 (83) 61 (79) 57 (81)
Refractive status
Myopia 4 (5) 6 (8) 4 (6) 0.81
Hyperopia 23 (30) 17 (22) 19 (27)
Emmetropia 49 (64) 54 (70) 47 (67)
Mean refractive error (SE)† 0.47 (0.11) 0.41 (0.17) 0.46 (0.20) 0.96
Data are the number of subjects with the percentage of the total group in parentheses, except for mean refractive error, which is the mean  SE.
* There were two missing values.
† P derived through ANOVA.
TABLE 2. Effectiveness of the Cycloplegic Agents: Residual Accommodation, Pupillary Dilatation, Pupillary Response and Side Effects
Cyclopentolate
(n  76)
Combined Regimen
(n  77)
Atropine
(n  70)
P
Pearson 2
Residual accommodation
0.0–0.5 D 41 (54) 55 (71) 70 (100) 0.0001
0.5–1.0 D 24 (32) 19 (25) 0 (0)
1.0–1.5 D 8 (11) 2 (3) 0 (0)
1.5 D 3 (4) 1 (1) 0 (0)
Dilated pupil size
6 mm 36 (47) 5 (6) 0 (0) 0.0001
6 mm 40 (53) 72 (94) 70 (100)
Response to light
Negative 19 (25) 51 (66) 68 (97) 0.0001
Positive 57 (75) 26 (34) 2 (3)
Side effects of agent*
None 54 (71) 55 (71) 65 (93) 0.001
Yes 22 (29) 22 (29) 5 (7)
Data are the number of subjects with the percentage of the total group in parentheses.
* All side effects were mild. Prolonged blurry near vision was not included, as only children in the atropine group were reviewed 3 days after
the initial examination.
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Cost
The cost of the agent for each treated child was £0.07 for 1%
atropine, £0.05 for 1% cyclopentolate and £0.12 for the com-
bined regimen (Table 3). Travel costs and carer’s wages lost
were similar in the three groups. The children’s school fees lost
were significantly higher in the atropine group than the other
groups. Overall, the median total costs were significantly
higher in the atropine group (£2.27) than in the cyclopentolate
(£2.08, P  0.01) or the combined-regimen (£1.72, P  0.01)
group. Costs were significantly higher in the cyclopentolate
than in the combined-regimen group (P  0.01).
Cost Effectiveness
The effectiveness unit was a 1-D decrease in residual accom-
modation. The cost unit was a 1-£ increase in cost. The ICER
was the additional cost per 1-D decrease in residual accommo-
dation for one agent compared to another. Atropine was more
expensive than the combined regimen, but also more effective,
with an ICER of 1.81 (95% CI  0.61–4.28; Table 4). This
indicated that atropine costs an additional £1.81 per 1-D de-
crease in residual accommodation achieved. Atropine was also
more expensive and more effective than cyclopentolate, giving
an ICER of 0.59 (95% CI  0.81–1.98), or £0.59 per 1-D
decrease in residual accommodation achieved. The combined
regimen was cheaper than cyclopentolate and achieved lower
levels of residual accommodation, and therefore it was the
superior treatment with an ICER of 0.85 (95% CI  5.26–
2.16). All confidence intervals included the null value, indicat-
ing that no agent was significantly more cost-effective than the
other. The estimates of the ICER calculated from the bootstrap
method were close to the true population ICER (data not
shown), and so the bias-corrected percentile method was not
used. Figure 2 shows the bootstrap results of the comparison
of costs and effectiveness of cycloplegic agents, with 95% CIs,
plotted on the cost-effectiveness plane. It illustrates that atro-
pine was more effective than either the combined regimen or
cyclopentolate and that the combined regimen was more ef-
fective than cyclopentolate. There was greater variation, how-
ever, in the relative costs of the treatments.
DISCUSSION
Cycloplegic refraction is necessary for measuring refractive
error accurately in children; however, the cycloplegic agent of
choice for children with dark irides has not yet been estab-
lished. This randomized controlled trial in Nigerian children
showed that atropine was a more effective cycloplegic agent
than either a combined regimen of tropicamide and cyclopen-
tolate or cyclopentolate alone. The children in the atropine
group had superior results in terms of lower mean residual
accommodation, with a higher proportion having a negative
response to light and adequate dilated pupil size. The com-
bined regimen was better on all these scales compared to
cyclopentolate alone. The combined regimen and cyclopento-
late groups reported more side effects on instillation than the
atropine group, although side effects were assessed immedi-
ately after administration of drops for the combined and cyclo-
pentolate groups, but after a 3-day interval in the atropine
group. All the children in the atropine group complained of
prolonged blurry near vision when they presented at the eye
clinic 3-days after the initial examination, whereas the other
children were not re-examined 3-days later. Costs in the atro-
pine group were marginally higher than in the other groups,
because two trips were required by the carer and child rather
than the single trip for the other agents. The costs per child
were significantly lower for the combined regimen than for
cyclopentolate, which is surprising because both regimens
required only one trip for the carer and child. This significant
difference is probably due to random variation in the data, as
there is no obvious alternative explanation. Overall, combined
cyclopentolate and tropicamide was more effective than cyclo-
pentolate alone, but not more expensive. Atropine was both
more expensive and more effective than cyclopentolate or the
combined regimen, but had far higher losses to follow-up.
Our results support those in other studies that show the
superior effectiveness of atropine in suppressing accommoda-
tion in children with dark irides. In a study of 50 Japanese
children, the average refractive error obtained by autorefractor
was 0.7 D higher in children after instillation of atropine drops
(0.5% or 1% twice daily over 7 days) compared with cyclopen-
TABLE 3. Costs Per Patient Associated with the Three Intervention Arms
Costs (£)
Cyclopentolate
(n  76)
Combined Regimen
(n  77)
Atropine
(n  70)
P
Pearson 2
Study medication
Drops 0.05 (100) 0.12 (100) 0.07 (100)
Direct patient costs
Travel
0 52 (68) 57 (74) 54 (77) 0.48
0–9.620 24 (32) 20 (26) 16 (23)
Extra cost
0 71 (93) 71 (92) 63 (90) 0.75
0–2.0 5 (7) 6 (8) 7 (10)
Productivity costs
Children’s school fees lost
0 19 (25) 19 (25) 19 (27) 0.0001
0–0.1 52 (68) 51 (66) 17 (24)
0.1–9.4 5 (7) 7 (9) 34 (49)
Carer’s wages lost
0 30 (39) 31 (40) 19 (27) 0.27
0–2.0 33 (43) 37 (48) 35 (50)
2.0 13 (17) 9 (12) 16 (23)
Median total costs (interquartile range) 2.08 (0.14–2.20) 1.72 (0.22–2.22) 2.27 (1.27–3.31) 0.01*
Mean total costs (SE)† 2.37 (0.33) 2.14 (0.28) 2.72 (0.30) 0.40†
Data are number with percentage of the total group in parentheses, except where otherwise noted.
* Kruskal-Wallis test.
† ANOVA.
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tolate 1% (instilled three times every 5 minutes).19 In 25 Chi-
nese children with pigmented irides, atropine 1% (applied
twice daily over 3 days) detected a higher degree of hyperopia
(5.7 D) compared with a combined regimen of cyclopento-
late 1% and tropicamide 1% (5.3 D).15 The main disadvantage
of atropine; however, is that it requires examination of chil-
dren a few days after administration, and this may have con-
tributed to the high loss to follow-up experienced in the
atropine group in our study. Atropine can also produce severe
side-effects (mainly due to its anticholinergic action), although
longer term side effects (e.g., ultraviolet light damage to the
lens and the retina as a result of chronic pupillary dilatation
from long-term use of atropine) are unlikely to occur if atro-
pine is used only for diagnostic purposes.20 The inadequateTA
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FIGURE 2. Representation of the uncertainty in differential mean costs
and effectiveness showing 1000 bootstrap replications, with 95% CI.
Horizontal axis: difference in mean residual accommodation; vertical
axis: difference in mean cost. (a) Atropine was significantly more
effective than the combined regimen, but not more expensive. (b)
Atropine was significantly more effective than cyclopentolate, but not
more expensive. (c) The combined regimen was significantly more
effective than cyclopentolate, but not more expensive.
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cycloplegia attained by cyclopentolate shown by other stud-
ies2,8,9 is consistent with our findings, in which 15% of chil-
dren had a residual accommodation of1 D. Tropicamide may
boost mydriasis in cyclopentolate in children with dark irides,
and this may be the best alternative to atropine,14 as shown by
the present study. No previous cost-effectiveness study has
been conducted on these agents in a low-income setting to
allow comparison of results.
Study Limitations
This study was too small to find statistically significant differ-
ences in ICERs or to assess differences in the effectiveness of
the cycloplegic agents between age groups. The hospital costs
were not recorded (except for the direct costs of the drugs),
since the time spent with the child by the ophthalmologist and
optometrist was assumed to be the same for all three interven-
tion arms. Masking of the optometrist was incomplete, because
the cyclopentolate and combined-regimen groups were exam-
ined 30 minutes after instillation of drops, whereas the atro-
pine group was examined after 3 days. Side effects for cyclo-
pentolate and the combined regimen were assessed on the
same day as the instillation of drops, whereas the atropine
group was questioned about side effects after 3 days, which
may have contributed to the difference in reported side effects.
The duration of side effects was also not assessed, although
side effects tended to be mild and apparent mainly on instilla-
tion of drops.
Study Strengths
We used a randomized controlled trial to assess the effective-
ness of the cycloplegic agents, a question that has not been
answered previously for an African population. We used the
trial as a framework for economic evaluation and this allowed
us to collect and analyze patient-specific resource use data. The
same optometrist performed all the refractions. This was an
effectiveness study rather than an efficacy study, as we did not
use expensive equipment so that our study results would
reflect the real-world circumstances of the African hospital.
The CONSORT (Consolidated Standards of Reporting Trials)
guidelines were adhered to for the trial.21
Public Health Implications
Inadequate cycloplegia may result in overdiagnosis of myopia
and underdiagnosis of hyperopia, and a distortion of the mag-
nitude of refractive errors among African children. Accurate
cycloplegia is therefore important, but until now no random-
ized controlled trials have been undertaken in African children
to identify the most cost-effective cycloplegic agent. This study
confirms that atropine is more effective than cyclopentolate or
the combined regimen, although it is not ideal for use in
routine clinical practice because of the high loss to follow-up,
and the prolonged impaired near vision produced by atropine
may also reduce participation in trials, cohort studies, and
surveys. Cyclopentolate was less effective but not cheaper than
the combined regimen of cyclopentolate and tropicamide and
may yield unreliable data on examinations in children. This
implies that the combination of cyclopentolate and tropicam-
ide should become the recommended cycloplegic agent of
choice for routine cycloplegic refraction and large-scale studies
of refractive error in African children. Atropine may remain the
agent of choice, however, when a very accurate refraction is
needed, such as for children with esotropia. Relative costs and
effectiveness of the three regimens may vary between popula-
tions, and therefore more studies are needed before assessing
whether the results are generalizable to other populations,
although this may be less of an issue on the African continent.
Summary
Atropine was the most effective cycloplegic agent, but had
practical limitations due to its requirement for examination
after 3 days of treatment and consequent high loss to follow-
up. A combination of cyclopentolate and tropicamide was
more effective than cyclopentolate alone, but not more expen-
sive, and should become the recommended cycloplegic agent
of choice for routine cycloplegic refraction in African children.
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